Expert Forum: Bladder Cancer

EP1: Expert Forum on Bladder Cancer: The BCG shortage

November 22nd 2021

“Fortunately, since things have…eased up with the pandemic, I would say probably in the last 6 months I've noticed that the BCG availability has improved,” says Chad R. Ritch, MD, MBA, FACS.

EP2: Expert Forum on Bladder Cancer: Bladder-sparing treatment

November 23rd 2021

“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.

EP3: Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC

November 26th 2021

“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.

EP4: Expert Forum on Bladder Cancer: Recent FDA approvals

November 29th 2021

“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.

EP5: Expert Forum on Bladder Cancer: Recent Innovations

December 1st 2021

“We are having a wealth of new medications that are helping our patients. Primarily with advanced disease, but…maybe there are going to be some applications to move that earlier and earlier in the in the disease process,” says Christopher B. Anderson, MD, MPH.

EP6: Expert Forum on Bladder Cancer: Future Innovations

December 10th 2021

“I have no doubt that within 10 years…what we've been basing our treatment strategies and surveillance strategies of high-grade…papillary disease is still going to be there. But, in reality, we're really going to have a much better idea of individual risk stratification and characteristics of their tumors,” says Sam S. Chang, MD, MBA.